Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846547 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
A Phase 2 study, sponsored by Seaside Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00846547: Completed Phase 2 study, sponsored by Seaside Therapeutics.
NCT00846547 is a Phase 2 study that has completed, run by Seaside Therapeutics. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00846547, a Phase 2 study, has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability. We hypothesize that STX209 will be safe and well-tolerated.
Interventions
- DRUG Arbaclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846547
The ClinicalTrials.gov registry entry for NCT00846547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arbaclofen is the first listed.
NCT00846547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846547 about?
NCT00846547 is a clinical study titled "Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders". The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability. We hypothesize that STX209 will be safe and well-tolerated.
What is the current status of trial NCT00846547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2009-02. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00846547?
The interventions under investigation include: Arbaclofen (DRUG).
Who is sponsoring clinical trial NCT00846547?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.